NYSE:ENZ Enzo Biochem (ENZ) Stock Forecast, Price & News $2.29 0.00 (0.00%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$2.25▼$2.3350-Day Range$2.04▼$2.6652-Week Range$1.00▼$2.75Volume110,050 shsAverage Volume134,832 shsMarket Capitalization$113.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Enzo Biochem (NYSE:ENZ) StockEnzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.Read More Receive ENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZ Stock News HeadlinesMay 22, 2023 | finanznachrichten.deEnzo Biochem, Inc.: Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset SaleMay 22, 2023 | finance.yahoo.comEnzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset SaleMay 28, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 18, 2023 | americanbankingnews.comEnzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.comMay 14, 2023 | finance.yahoo.comEnzo Biochem Insiders Added US$11m Of Stock To Their Holdings \May 13, 2023 | marketwatch.comNon-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Forecast 2023-2031 with Size and ShareMay 4, 2023 | marketwatch.comGlobal Blood Screening Market by [2023-2029] with Revenue OutsourcingMay 3, 2023 | marketwatch.comWound Healing Assay Kits Market Analysis and Forecast to 2031May 28, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 3, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.April 28, 2023 | marketwatch.com2023-2030 Non-Radioactive Nucleic Acid Labeling Product Market Growth Developments with Latest UpdatesApril 28, 2023 | msn.comEnzo Biochem in Farmingdale to Lay Off 247 EmployeesApril 28, 2023 | marketwatch.comGlobal Monensin Market Share 2023-2030 with On-going Demand StatusApril 24, 2023 | finance.yahoo.comEnzo Biochem, Inc. Announces Date of Special Meeting of ShareholdersApril 23, 2023 | americanbankingnews.comEnzo Biochem (NYSE:ENZ) Now Covered by StockNews.comApril 19, 2023 | marketwatch.comFlow Cytometry Market | Latest Updates and Forecast to 2031April 17, 2023 | finance.yahoo.comEnzo Biochem (NYSE:ENZ) shareholders have endured a 58% loss from investing in the stock five years agoApril 15, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)April 13, 2023 | americanbankingnews.comComparing Akumin (NASDAQ:AKU) & Enzo Biochem (NYSE:ENZ)April 7, 2023 | marketwatch.com8-K: ENZO BIOCHEM INCApril 7, 2023 | americanbankingnews.comEnzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.comMarch 31, 2023 | marketwatch.comNucleic Acid Labeling Market 2023 Growth, Trend and Outlook till 2031March 26, 2023 | americanbankingnews.comEnzo Biochem (NYSE:ENZ) vs. Aclarion (NASDAQ:ACON) Head-To-Head ContrastMarch 24, 2023 | marketwatch.comClinical Reference Laboratory Services Market Outlook and Forecast till 2031March 24, 2023 | marketwatch.comNonAlcohlic Steatohepatitis (Nash) Market Premium Research Report Forecast 2023 To 2029March 23, 2023 | marketwatch.comPD-173955 Market: Trends and Innovations Shaping the Future Industry 2023-2027March 23, 2023 | marketwatch.comProtein Stability Analysis Market Premium Research Report Forecast 2023 To 2029See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZ Company Calendar Last Earnings3/20/2023Today5/28/2023Next Earnings (Estimated)6/08/2023Fiscal Year End7/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:ENZ CUSIPN/A CIK316253 Webwww.enzo.com Phone(212) 583-0100Fax212-679-7999Employees451Year Founded1976Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,260,000.00 Net Margins-43.44% Pretax Margin-43.44% Return on Equity-67.73% Return on Assets-36.44% Debt Debt-to-Equity Ratio0.01 Current Ratio1.13 Quick Ratio0.64 Sales & Book Value Annual Sales$81.12 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book2.04Miscellaneous Outstanding Shares49,663,000Free Float41,965,000Market Cap$113.73 million OptionableOptionable Beta1.04 Social Links Key ExecutivesHamid ErfanianChief Executive Officer & DirectorKara CannonChief Operating OfficerPatricia EckertChief Financial OfficerDieter SchapfelChief Medical DirectorMatthew KupferbergSecretary & General CounselKey CompetitorsSera PrognosticsNASDAQ:SERAPersonalisNASDAQ:PSNLBiodesixNASDAQ:BDSXGenetronNASDAQ:GTHMedTech AcquisitionNASDAQ:MTACView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 27,023 shares on 5/16/2023Ownership: 0.054%Snowden Capital Advisors LLCSold 6,605 shares on 5/16/2023Ownership: 0.045%Susquehanna International Group LLPSold 9,585 shares on 5/16/2023Ownership: 0.038%Cubist Systematic Strategies LLCBought 19,985 shares on 5/15/2023Ownership: 0.040%Belvedere Trading LLCSold 35,300 shares on 5/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ENZ Stock - Frequently Asked Questions How have ENZ shares performed in 2023? Enzo Biochem's stock was trading at $1.43 at the beginning of the year. Since then, ENZ stock has increased by 60.1% and is now trading at $2.29. View the best growth stocks for 2023 here. Are investors shorting Enzo Biochem? Enzo Biochem saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,220,000 shares, an increase of 8.9% from the April 15th total of 1,120,000 shares. Based on an average trading volume of 849,700 shares, the short-interest ratio is currently 1.4 days. Currently, 3.7% of the company's shares are sold short. View Enzo Biochem's Short Interest. When is Enzo Biochem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 8th 2023. View our ENZ earnings forecast. How were Enzo Biochem's earnings last quarter? Enzo Biochem, Inc. (NYSE:ENZ) released its earnings results on Monday, March, 20th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter. The medical research company had revenue of $16.34 million for the quarter. Enzo Biochem had a negative net margin of 43.44% and a negative trailing twelve-month return on equity of 67.73%. What other stocks do shareholders of Enzo Biochem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU). What is Enzo Biochem's stock symbol? Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ." Who are Enzo Biochem's major shareholders? Enzo Biochem's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.58%), Dimensional Fund Advisors LP (3.06%), BlackRock Inc. (2.86%), Roumell Asset Management LLC (1.82%), Potomac Capital Management Inc. (1.57%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf and Kara Cannon. View institutional ownership trends. How do I buy shares of Enzo Biochem? Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enzo Biochem's stock price today? One share of ENZ stock can currently be purchased for approximately $2.29. How much money does Enzo Biochem make? Enzo Biochem (NYSE:ENZ) has a market capitalization of $113.73 million and generates $81.12 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. How many employees does Enzo Biochem have? The company employs 451 workers across the globe. How can I contact Enzo Biochem? Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999. This page (NYSE:ENZ) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzo Biochem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.